## MBA PHARMA

Curriculum MAP PHARMA HR 2023 - 24			Goal 1: To develop an understanding of dynamics shaping globalbusiness			Goal 2: To develop Critical thinking skills Goal 3 -Ai			Goal 3 -An int	n integrative approach to decision aking and problem solving		Goal 4- To develop technological orientatation and fluency			ion and digital	d digital Goal 5: Effective commun		ication Skills		Goal 6: To sharpen leadership & Interpersonal Skills		Goal 7: An understanding of ESG challenges impacting business				
					1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
Sr. No	Trimester	Course Name	Credit	Area	PLO 1a	PLO 1b	PLO 1c	P LO 2a	P LO 2b	P LO 2c	P LO 3a	PLO 3b	PLO 3c	PLO 4a	PLO 4b	PLO 4c	PLO 4d	PLO 5a	PLO 5b	PLO 5c	PLO 6a	PLO 6b	PLO 6c	PLO 7a	PLO 7b	
1	TRIM I	Business Environment	3	BES		CLO 3			CLO 2			CLO 1 CLO 4												<del>                                     </del>		
2	TRIM I	Principles of Management	1.5	BES				CLO 1	CLO 2			CLU 4		CLO3		CLO 4										+
3	TRIM I	Managerial Communication I	1.5	COMM														CLO2	CLO1	CLO3						
4	TRIM I	Microeconomics	3	ECO				CLO 1	CLO 2	CLO 3									CLO 4						<del></del>	+
5	TRIM I	Financial Accounting and Analysis	3	FIN							CLO 2									CLO 1						
6	TRIM I	Organizational Behaviour 1	3	HRBS	CLO1			CLO2			CLO 3													CLO3	<del></del>	+
7	TRIM I	Marketing Management I	3	MKT				CLO 1	CLO 2		CLO 3															T
- 8	TRIM I	Listening to Customers- I	3	MKT				CLO 1		CLO 2										CLO 3			CLO 4			1
9	TRIM II	Indian Healthcare System and Regulation	1.5	BES	CLO 3	CLO 1				CLO 2																
10	TRIM II	Business Laws	1.5	BES				CLO 1			CLO2													i		
11	TRIM II	Managerial Communication II	1.5	COMM														CLO1	CLO 2	CLO 3						1
12	TRIM II	Macroeconomics	3	ECO	CLO 1	CLO 2											1								CLO 3	<b>†</b>
13	TRIM II	Cost and Management Accounting	1.5	FIN	CLO I	CLO L			CLO 1			CLO 2	CLO 3												020 5	t
	TRIM II	Organizational Behavior II	1.5	HRBS	1	CLO 3	CLO 4	CLO 1	CLO 2			CLO 2	CLO J		1	1	1	l		-			$\vdash$	$\vdash$	<b></b>	t
15	TRIM II	Listening to Customers- II	3	MKT	+	CLU 3	CLU 4	CLO 1	CLU 2	CLO 2					<b> </b>	+	<del>                                     </del>	-		CLO 3			CLO 4	$\overline{}$		+
				MKT	-	1				CLU Z	CLO 4	CLOS				-	1			CLU 3	CLOD		CLU 4	$\vdash$	-	+
16	TRIM II	Managing Sales in Pharma	1.5					CLO 1			CLO 4	CLO 2									CLO 3			$\vdash$	<b>├</b>	
17	TRIM II	Research Methodology and Marketing Research	3	MKT	1	1			CLO 1	CT O C						1	CLO 2			CLO 3						+
18	TRIM II	Statistics and Optimization Techniques	3	ODS					CLO 2	CLO 3		CLO1 CLO 4													<del></del>	
10				222					CLO 1	CLO 2			CLO 4													
19	TRIM III	Strategic Management	3	BES					CLO I	CLO 3																1
20	TRIM III	Entrepreneurship in Healthcare	1.5	BES	CLO 1			CLO 3		CLOS							CLO 2									<del>                                     </del>
21	TRIM III	Financial Management	3	FIN					CLO 1			CLO 3														
22	TRIM III	Human Resource Management	3	HRBS		CLO1			CLO 2 CLO2			CLO3												$\vdash$	<del></del>	<del> </del>
	TRIM III		1.5	MKT	-	CLUI		CI O 4	CLO 2		CLOD	CLU3												-	<del>                                     </del>	+
	TRIM III		3	MKT				CLO 1 CLO 1	CLO 2		CLO 3 CLO 2				CLO 4	+	CLO 3							-	<del></del>	+
	TRIM III	Technology Applications in Pharma	3	ODS				CLO1			CLU Z				CLU 4	+	CLO3							-	<del></del>	+
	TRIM III	Operations Management	1.5	ODS				CLO 3			CLO 1	CLO 2					CLOZ								<del>                                     </del>	+
	TRIM IV	Management Consulting	3	BES		CLO 3		CLO 3	CLO 2		CLOI	CLO 1													<del>                                     </del>	+
						CLOS			CLO 4	CLO 1		CLOI	CLO 3												<del>                                     </del>	+
28	TRIM IV	Strategy Implementation and Control	1.5	BES					CLO 4	CLO 2			CLOS													
29	TRIM IV	Negotiation Skills and Process	1.5	COMM																			CLO 1	$\vdash$	<del> </del>	-
29	I KIIVI I V	Negotiation Skins and Frocess	1.5	COMM																			CLO 2 CLO 3	$\vdash$	<del></del>	+
20	TDIMIN	To all the Hill of MV III a		HRBS				CI O 2													CLOI	CLO 3	CLU 3	$\vdash$	<del></del>	
	TRIM IV		1.5					CLO 2													CLO1	CLO 3			<del>                                     </del>	
	TRIM IV TRIM IV	Product Management	1.5	MKT MKT	+	0.07	-	0.0.4	CLO 2	CLO 4	CLO 3	CLO 1	0.00		<b>-</b>	-	<del>                                     </del>	-	-	-			$\vdash$			+
	TRIM IV	New Product Launch Brand Management	3	MKT	1	CLO 1		CLO 4	CLO 1	CLO 2 CLO 3		CLO 2	CLO 3 CLO 4			-	1						$\vdash$	$\vdash$	-	+
	TRIM IV	Sales Forecasting and Analytics	1.5	ODS	1	1			CLO 1	CLU 3		CLU Z	CLU 4		CLO 1	-	1						$\vdash$	$\vdash$	-	+
35	TRIM V	Corporate Social Responsibility	1.5	BES	CLO 1	1	-		CLU 2						CLO 1	1	1			-			$\vdash$	CLO 2	CLO 3	CLO 4
	TRIM V	Ethics & Compliance	1.5	BES	CLO 1	CLO 1	-	CLO 2							1	1	1			-			$\vdash$	CLU Z	CLU 3	CLU 4
37	TRIM V	Business Valuation and Mergers & Acquisition	3	FIN	1	CLO 1	-	CLU Z				CLO 3			1	1	1		CLO 4	-			$\vdash$			CLO 2
	TRIM V	Health Economics	3	ECO	CLO 1	CLU I		CLO 2		<b>—</b>	CLO 3	CLU 3			<del>                                     </del>	+	<del>                                     </del>		CLU 4	-			$\vdash$			LLU 2
					CLU I	1		CLO 2			CLO 3				<u> </u>	+	1			CLO 4			$\vdash$	$\vdash$	$\vdash$	+
	TRIM V	Pricing Strategy in Pharma	1.5	MKT				CLO 3												CLO 4						
	TRIM V	Brand Marketing Plan	3	MKT				CLO 1	CLO 3		CLO 2															
	TRIM V	Supply Chain Management	1.5	ODS	CLO 1	CLO 4			CLO 2		CLO 3													<u> </u>		
	TRIM V	Project Management	1.5	ODS	CLO 1				CLO 2	CLO 3														<u> </u>		
	TRIM VI		1.5	BES		CLO 1																CLO 4		<u> </u>	CLO 3	CLO 2
	TRIM VI		1.5	BES		1		CLO 1	ļ		CLO 2					1	1	ļ					<u> </u>	<b>└</b> ──'	<u> </u>	↓
	TRIM VI	Managing IPR in Pharma	1.5	BES		1		CLO 1	ļ		CLO 2					1	1	ļ						<b>└</b>	<b>↓</b>	
	TRIM VI	International Marketing	3	MKT	1	CLO 1	CLO 2		ļ	CLO 3		CLO 4				1	1	ļ						<b>└</b>	<b>↓</b>	1
47	TRIM VI	Good manufacturing Practices & Regulatory approvals	1.5	ODS	CLO 1				CLO 2																	
						1	1	1	CLO 3	1		1 1		l .				1	1	1					1	1
	TRIM VI	Managing Innovation in Pharma & R&D TOTAL	1.5	ODS	CLO 1				CLO 2														Ļ	L	L	

Description	PLO	SUB PLO	COUNT OF CLO	% COUNT OF CLO's to sub PLO's	TOTAL	%
Goal 1: To develop an	PLO1	PLO 1a	10	6.4%		
understanding of dynamics		PLO 1b	12	7.7%	24	15.4%
shaping globalbusiness		PLO 1c	2	1.3%		
	PLO2	P LO 2a	23	14.7%		
Goal 2: To develop Critical thinking skills		P LO 2b	23	14.7%	60	38.5%
		P LO 2c	14	9.0%		
Colla Asimondia	PLO3	P LO 3a	15	9.6%	34	
Goal 3 -An integrative approach to decision making		PLO 3b	14	9.0%		21.8%
and problem solving		PLO 3c	5	3.2%		
Cool 4 To dovelon	PLO4	PLO 4a	1	0.6%	8	
Goal 4- To develop		PLO 4b	2	1.3%		5.1%
technological orientatation and digital fluency		PLO 4c	1	0.6%		3.176
digital fluency		PLO 4d	4	2.6%		
Goal 5: Effective	PLO5	PLO 5a	2	1.3%	13	
communication Skills		PLO 5b	4	2.6%		8.3%
Communication Skins		PLO 5c	7	4.5%		
Goal 6: To sharpen leadership	PLO6	PLO 6a	2	1.3%		
& Interpersonal Skills		PLO 6b	2	1.3%	9	5.8%
& filter per sonar Skins		PLO 6c	5	3.2%		
Goal 7: An understanding of		PLO 7a	2	1.3%		
ESG challenges impacting	PLO7	PLO 7b	3	1.9%	8	5.1%
business		PLO 7c	3	1.9%		
TOTOL				156	<u> </u>	100

PLO	COUNT OF CLO	% COUNT OF CLO's to sub PLO's
PLO1	24	15.4%
PLO2	60	38.5%
PLO3	34	21.8%
PLO4	8	5.1%
PLO5	13	8.3%
PLO6	9	5.8%
PLO7	8	5.1%
TOTAL	156	100.0%

Description	PLO	%					
Goal 1: To develop an understanding of dynamics shaping globalbusiness	PLO1	15%					
Goal 2: To develop Critical thinking skills	PLO2	38%					
Goal 3 -An integrative approach to decision making and problem solving	PLO3	22%					
Goal 4- To develop technological orientatation and digital fluency	PLO4	5%					
Goal 5: Effective commumication Skills	PLO5	8%					
Goal 6: To sharpen leadership & Interpersonal Skills	PLO6	6%					
Goal 7: An understanding of ESG challenges impacting business	PLO7	5%					
TOTAL							



